against Cancer 55 th HEIDELBERG GRAND ROUNDS Chairs: Prof. Dr. Christof von Kalle Prof. Dr. Dirk Jäger Prof. Dr. Peter Krammer

Size: px

Start display at page:

Download "against Cancer 55 th HEIDELBERG GRAND ROUNDS Chairs: Prof. Dr. Christof von Kalle Prof. Dr. Dirk Jäger Prof. Dr. Peter Krammer"

Katrina Crawford
6 years ago
Views:

1 55 th HEIDELBERG GRAND ROUNDS BIG SHOTS against Cancer Chairs: Prof. Dr. Christof von Kalle Prof. Dr. Dirk Jäger Prof. Dr. Peter Krammer October 25 th, Lecture Hall, DKFZ Communication Center

2 55 th HEIDELBERG GRAND ROUNDS BIG SHOTS against Cancer Alexander Eggermont Gustave Roussy Cancer Campus, Paris Unblocking a Blocked Immune System: The New Starting Point Jordi Rodon Vall Hebron Institute of Oncology (VHIO), Barcelona Drugs for Small Patient Populations. Design of Clinical Trials Michel Sadelain Memorial Sloan Kettering Cancer Center, New York The Promise of T-cell Engineering John Mendelsohn Director of the Khalifa Institute for Personalized Cancertherapy and Past President, University of Texas MD Anderson Cancer Center Precision Cancer Medicine: A 36 Year Personal Journey

3 Michel Sadelain Michel Sadelain is Head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan- Kettering Cancer Center (MSK). Dr. Sadelain s research focuses on novel approaches to enhance T cell costimulation and function. His clinical program focuses on B cell malignancies as well as solid tumors. Dr. Sadelain is the incumbent of the Stephen and Barbara Friedman Chair and the founding director of the Center for Cell Engineering at MSK. He previously served on the Board of Directors of the American Society of Gene Therapy ( ) and continues to serve on the editorial boards of Molecular Therapy, Human Gene Therapy and Gene Therapy.

Jordi Rodon Jordi Rodon is attending physician at the Medical Oncology department of Vall d Hebron University Hospital and Clinical Coordinator of the Molecular Therapies Research Unit (UITM).

4 Jordi Rodon Jordi Rodon is attending physician at the Medical Oncology department of Vall d Hebron University Hospital and Clinical Coordinator of the Molecular Therapies Research Unit (UITM). He went to Medical School at Universitat Autònoma de Barcelona-Vall d Hebron University Hospital, and got his specialization in Medical Oncology at the Catalan Institute of Oncology (Institut Català d Oncologia). He has been Research fellow at the Advanced Drug Development Fellowship program at the Institute For Drug Development in San Antonio, Texas, and Senior Research fellow at the Investigational Cancer Therapeutics Department at MD Anderson Cancer Center in Houston, Texas. He joined the Medical Oncology Department in 2008 and has been principal investigator or co-investigator in more than 80 phase I trials. At Vall d Hebron, he coordinates the phase I program and the traslational research at UITM, as well as projects in Personalized Oncoligy, being member of Stand-up-to-cancer, Eurocan and WIN Consortium.

John Mendelsohn John Mendelsohn, recently completed 15 years as President of MD Anderson Cancer Center during a period of tremendous growth, and he currently directs its Institute for Personalized

5 John Mendelsohn John Mendelsohn, recently completed 15 years as President of MD Anderson Cancer Center during a period of tremendous growth, and he currently directs its Institute for Personalized Cancer Therapy. Previously he was founding director of the UCSD Cancer Center, and Chair of Medicine at Memorial Sloan-Kettering Cancer Center. His team s research led to the production, preclinical and clinical investigation and regulatory approval of an anti-egf receptor monoclonal antibody, cetuximab. Their 1983 publication was the first report of inhibition of cancer growth by blocking activation of a tyrosine kinase. He chairs the Houston Grand Opera and enjoys tennis and the out of doors with his family.

6 Alexander M.M. Eggermont Alexander M.M. Eggermont is Director General of Gustave Roussy Comprehensive Cancer Center, Cancer Campus Grand Paris. He is full Professor of Oncology ( ) (Classe Exceptionnelle) at the Paris-Sud University in Paris. Full Professor of Surgical Oncology ( ) as well as Endowed Professor of International Networking in Cancer Research ( ) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA. His clinical specialties include immunotherapy, melanoma, sarcoma and regional therapy techniques as well as general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models and tumor pathophysiology.

7 Heidelberg Grand Rounds (HGR) Ground Rules The HGR have been established as a forum to bring together basic scientists and clinicians. Distinguished experts present novel clinical and research findings and provide a comprehensive update in the respective field of oncology. In addition to the high-ranking scientific and clinical presentations, the HGR also constitute a casual get-together, seasoned with drinks and refreshments, to foster a lively atmo sphere for continued discussion.

8 Please register by 24 th October at the latest. For this event, two points for continuing education will be given by the Landesärztekammer. Within the practical year, the points will be recognized in the field of internal medicine and surgery. Information and registration: Fortbildungs- und Veranstaltungs organisation des Nationalen Centrums für Tumorerkrankungen Heidelberg School of Oncology Im Neuenheimer Feld Heidelberg Phone +49 (0) Fax +49 (0) Marketing sponsored by: AstraZeneca GmbH 1.000,00 Hexal AG 2.500,00 Janssen Cilag GmbH 1.000,00 Medac GmbH 750,00 Merck Serono GmbH 2.000,00 MSD Sharp & Dohme GmbH 500,00 Novartis Pharma GmbH 3.000,00 Roche Pharma AG 5.000,00 Roche Diagnostics GmbH 1.500,00

16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG

16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG 16 TH -17 TH 2015 NOVEMBER INNOVATIONS IN ONCOLOGY HEIDELBERG INNOVATIONS IN ONCOLOGY HEIDELBERG, NOVEMBER 16 TH - 17 TH 2015 German Cancer Research Center (DKFZ) Heidelberg - Germany Hosted by the National